MX379854B - Compuestos quimericos ramificados y lineales, polinucleotidos, usos y metodos para preparacion de los mismos. - Google Patents

Compuestos quimericos ramificados y lineales, polinucleotidos, usos y metodos para preparacion de los mismos.

Info

Publication number
MX379854B
MX379854B MX2017009542A MX2017009542A MX379854B MX 379854 B MX379854 B MX 379854B MX 2017009542 A MX2017009542 A MX 2017009542A MX 2017009542 A MX2017009542 A MX 2017009542A MX 379854 B MX379854 B MX 379854B
Authority
MX
Mexico
Prior art keywords
branched
polynucleotides
methods
linear
chimeralic
Prior art date
Application number
MX2017009542A
Other languages
English (en)
Other versions
MX2017009542A (es
Inventor
Gary S Ott
Holger Kanzler
Radwan Kiwan
Robert J Milley
Robert L Coffman
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of MX2017009542A publication Critical patent/MX2017009542A/es
Publication of MX379854B publication Critical patent/MX379854B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto quimérico ramificado de la fórmula (I): [D-L1-L2-(PEG)-L3]x-F (I), en donde de: D es un compuesto quimérico lineal; L1 es un primer enlazador que comprende un grupo alquiltio: L2 es un segundo enlzador que comprende un grupo succinimida; L3 es un tercer enlazador que comprende un grupo amida; PEG es de la fórmula -(OHC2CH2)n-, en donde n es un entero de 2 a 80; x es un entero de 3 a 300; y F es un copolímero ramificado de sacarosa y epiciorhidrina que tiene un peso molecular de aproximadamente 100,000 hasta aproxicmadamente 700,000 daltons y está conectado a L3 vía un grupo éter, en donde el compuesto quimérico lineal de D comprende tres porciones de ácido nucleico y dos separadores de hexaetilenglicol porciones de ácido nucleico y dos separadores de hexaetilenglicol (HEG) como 5´-TCGGCGC-3´-HEG-5´-AACGTTC-3´-HEG-5´-TCGGCGC-3´(SEQ ID NO: 2), en donde el compuesto quimérico lineal contiene menos de 50 nucleótidos y en donde uno o más enlaces entre los nucleótidos, entre los nucleótidos y los separadores de HEG y entre el nucleótido 3´-terminal y L1 son enlaces de éster de fosforotioato.
MX2017009542A 2015-01-23 2016-01-22 Compuestos quimericos ramificados y lineales, polinucleotidos, usos y metodos para preparacion de los mismos. MX379854B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562107291P 2015-01-23 2015-01-23
PCT/US2016/014635 WO2016118932A1 (en) 2015-01-23 2016-01-22 Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof

Publications (2)

Publication Number Publication Date
MX2017009542A MX2017009542A (es) 2018-01-25
MX379854B true MX379854B (es) 2025-03-11

Family

ID=55447090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009542A MX379854B (es) 2015-01-23 2016-01-22 Compuestos quimericos ramificados y lineales, polinucleotidos, usos y metodos para preparacion de los mismos.

Country Status (11)

Country Link
US (3) US9950064B2 (es)
EP (1) EP3250232B1 (es)
JP (1) JP6646056B2 (es)
KR (1) KR20170100033A (es)
CN (1) CN107567335B (es)
AU (1) AU2016209027A1 (es)
CA (1) CA2974513A1 (es)
HK (1) HK1245635A1 (es)
MX (1) MX379854B (es)
SG (1) SG11201705913UA (es)
WO (1) WO2016118932A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR20170100033A (ko) 2015-01-23 2017-09-01 다이나박스 테크놀로지 코퍼레이션 분지형 및 선형 키메라 화합물, 폴리뉴클레오티드, 그것들의 용도 및 제조 방법
EP3442568A4 (en) * 2016-04-15 2019-12-18 Dynavax Technologies Corporation INTRATUMORAL ADMINISTRATION OF PARTICLES WITH A GREAT LIKE RECEPTOR 9 AGONIST AND A TUMORANTANT FOR TREATING CANCER
EP3481842A1 (en) 2016-07-11 2019-05-15 Mireca Medicines GmbH New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
EP3507295A1 (en) * 2016-08-31 2019-07-10 Mireca Medicines GmbH New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
CN111534434B (zh) * 2020-06-28 2022-07-05 江南大学 一种冻干保护剂及其在冻干青春双歧杆菌中的应用
CN117448337B (zh) * 2023-09-15 2025-11-28 安徽智飞龙科马生物制药有限公司 CpG寡聚脱氧核苷酸、包含其的佐剂、疫苗及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US8114418B2 (en) * 2001-06-21 2012-02-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—IV
KR20170100033A (ko) 2015-01-23 2017-09-01 다이나박스 테크놀로지 코퍼레이션 분지형 및 선형 키메라 화합물, 폴리뉴클레오티드, 그것들의 용도 및 제조 방법

Also Published As

Publication number Publication date
US20160213774A1 (en) 2016-07-28
CN107567335B (zh) 2021-10-29
WO2016118932A1 (en) 2016-07-28
KR20170100033A (ko) 2017-09-01
US20180360954A1 (en) 2018-12-20
US10350290B2 (en) 2019-07-16
CN107567335A (zh) 2018-01-09
HK1245635A1 (zh) 2018-08-31
US10548975B2 (en) 2020-02-04
US9950064B2 (en) 2018-04-24
CA2974513A1 (en) 2016-07-28
EP3250232A1 (en) 2017-12-06
MX2017009542A (es) 2018-01-25
EP3250232B1 (en) 2020-04-29
SG11201705913UA (en) 2017-08-30
AU2016209027A1 (en) 2017-08-10
JP6646056B2 (ja) 2020-02-14
JP2018504116A (ja) 2018-02-15
US20190240323A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX379854B (es) Compuestos quimericos ramificados y lineales, polinucleotidos, usos y metodos para preparacion de los mismos.
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
PH12018500718A1 (en) Compounds useful as modulators of trpm8
BR112018070934A2 (pt) proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
MX388301B (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
LT3294325T (lt) Car modifikuotų t ląstelių poveikio sustiprinimas nukleorūgšties vakcinacijos dėka
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
MX2014003979A (es) Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos.
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
EA201692219A1 (ru) Способы получения противовирусных соединений
MX389703B (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
SA518390788B1 (ar) مركب يستهدف إنترلوكين- 23 أ وعامل تنشيط الخلايا البائية واستخداماته
BR112016021345A8 (pt) Composições de vacina de molécula de ácido nucleico e usos das mesmas
BR112017004495A2 (pt) variantes de celobiohidrolase e polinucleotídeos codificando as mesmas
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CL2017002759A1 (es) Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
MA39900A (fr) Vaccins à base d'acide nucléique